Holen Sie sich die Stockscreener-App
5.17
3.19%
0.16
Handel nachbörslich:
4.92
-0.25
-4.84%
Schlusskurs vom Vortag:
$5.01
Offen:
$5.01
24-Stunden-Volumen:
682.57K
Relative Volume:
1.02
Marktkapitalisierung:
$676.35M
Einnahmen:
$25.81M
Nettoeinkommen (Verlust:
$-188.12M
KGV:
-3.5648
EPS:
-1.4503
Netto-Cashflow:
$-183.77M
1W Leistung:
+1.17%
1M Leistung:
+12.39%
6M Leistung:
+10.71%
1J Leistung:
-11.02%
1-Tages-Spanne:
$4.85
$5.18
1-Wochen-Bereich:
$4.80
$5.26
52-Wochen-Spanne:
$3.80
$7.91
Exscientia Plc Adr Stock (EXAI) Company Profile
Firmenname
Exscientia Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Exscientia Plc Adr Stock (EXAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
Exscientia Plc Adr Aktie (EXAI) Neueste Nachrichten
Quarterly Metrics: Quick and Current Ratios for Exscientia Plc ADR (EXAI) - The Dwinnex
Exscientia advances two drug programs with Sanofi By Investing.com - Investing.com South Africa
Exscientia advances two drug programs with Sanofi - Investing.com
How to interpret Exscientia Plc ADR (EXAI)’s stock chart patterns - US Post News
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? - MSN
Investing in Exscientia Plc ADR (EXAI) might be a great opportunity, but the stock is a bit undervalued - US Post News
Exscientia Plc ADR (EXAI)’s Market Momentum: Closing Strong at 5.06, Down -4.53 - The Dwinnex
Taking on analysts’ expectations and winning: Exscientia Plc ADR (EXAI) - SETE News
Exscientia's SWOT analysis: AI biotech stock faces merger, pipeline milestones - Investing.com
Exscientia Plc ADR (EXAI) expanding its growth trajectory ahead - SETE News
A stock that deserves closer examination: Exscientia Plc ADR (EXAI) - US Post News
Take off with Exscientia Plc ADR (EXAI): Get ready for trading - SETE News
Exscientia Plc ADR (EXAI)’s stock chart: A technical perspective - US Post News
Market Insights: Exscientia Plc ADR (EXAI)’s Notable Gain of 3.78, Closing at 5.22 - The Dwinnex
EXAI’s 52-Week Rollercoaster: From $3.80 to $7.91 – What’s Next for Investors? - The InvestChronicle
Closing Figures Unveiled: Exscientia Plc ADR (EXAI) Drop -1.02, Closes at 4.85 - The Dwinnex
EXAI (Exscientia Plc ADR) has impressive results - US Post News
Check out these key findings about Exscientia Plc ADR (EXAI) - SETE News
Exscientia Plc ADR (EXAI) Stock: A Year of Market Fluctuations - The InvestChronicle
Are Investors Keen On Selling Holdings In N2OFF Inc. (NASDAQ: NITO)? - Stocks Register
Daily Market Movement: Exscientia Plc ADR (EXAI) Sees a -1.77 Decrease, Closing at 5.56 - The Dwinnex
Ratios Reveal: Breaking Down Exscientia Plc ADR (EXAI)’s Financial Health - The Dwinnex
AI in Pharma and Biotech Market Projected Growth at 18.8% CAGR to Reach USD 13.1 billion by 2034 | Exclusive Research Report by Transparency Market Research Inc. - GlobeNewswire Inc.
Exscientia to Present at the Morgan Stanley 22 nd Annual Global Healthcare Conference - TT Nyhetsbyrån
Recursion Pharmaceuticals secures key shareholder support - Investing.com
What technical indicators reveal about EXAI stock - US Post News
Deeper Dive: Understanding Exscientia Plc ADR (EXAI) Through its Various Ratios - The Dwinnex
Have you been able to find a good deal on Exscientia Plc ADR’s shares? - US Post News
Exscientia Plc ADR (EXAI) Is Worth Accumulating At Current Levels - Stocks Register
EXAI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Market Resilience: Exscientia Plc ADR (EXAI) Finishes Strong at 5.00, Up 2.88 - The Dwinnex
Taking the lead: Exscientia Plc ADR (EXAI) - SETE News
Examining Exscientia Plc ADR (EXAI) stock is warranted - US Post News
Before Buying Exscientia Plc ADR (NASDAQ: EXAI) Stock, Read This First - Stocks Register
Exscientia stock downgraded to Hold amid Recursion merger - Investing.com
Recursion and Exscientia announce merger to enhance drug discovery - Investing.com
Biotech firm Recursion to buy smaller peer Exscientia for $688 million - Reuters
Views of Wall Street’s Leading Experts on Exscientia Plc ADR - SETE News
EXAI’s Debt-to-Equity Ratio at 0.06: What It Means for Exscientia Plc ADR’s Future - The InvestChronicle
Amazon (AMZN) Plunges 19.1% in a Month: Should You Buy the Dip? - Zacks Investment Research
Market Momentum: Exscientia Plc ADR (EXAI) Registers a -8.19 Decrease, Closing at 4.26 - The Dwinnex
Analyzing the Impact of Earnings Reports on Vivid Seats Inc Inc. (SEAT) Price Performance - The InvestChronicle
Exscientia Plc ADR (EXAI) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
A Deep Dive into Clear Channel Outdoor Holdings Inc. (CCO) Stock Performance - The InvestChronicle
Investor’s Toolkit: Key Ratios for Assessing Exscientia Plc ADR (EXAI)’s Performance - The Dwinnex
Balance Sheet Insights: Exscientia Plc ADR (EXAI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Exscientia gets buy rating, positive on asset control and trial plans - Investing.com
Exscientia takes full control of cancer drug program - Investing.com
The Exscientia Plc ADR (EXAI) had a good session last reading, didn’t it? - US Post News
This trade activity should not be overlooked: Exscientia Plc ADR (EXAI) - SETE News
Amazon (AMZN) Expands AWS Clientele With Exscientia Deal - Yahoo Finance
Finanzdaten der Exscientia Plc Adr-Aktie (EXAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):